HC Wainwright Reaffirms Buy Rating for Werewolf Therapeutics (NASDAQ:HOWL)

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $15.00 target price on the stock.

Separately, JMP Securities reduced their price target on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 14th.

Werewolf Therapeutics Trading Down 1.6 %

HOWL opened at $1.21 on Wednesday. The company’s 50 day moving average is $1.36 and its 200-day moving average is $1.82. Werewolf Therapeutics has a 1-year low of $1.03 and a 1-year high of $6.89. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. The company has a market cap of $53.92 million, a P/E ratio of -0.79 and a beta of 0.37.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. Equities research analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. D. E. Shaw & Co. Inc. acquired a new stake in Werewolf Therapeutics during the 4th quarter worth approximately $26,000. Regal Investment Advisors LLC boosted its position in Werewolf Therapeutics by 88.1% during the 4th quarter. Regal Investment Advisors LLC now owns 27,204 shares of the company’s stock worth $40,000 after buying an additional 12,745 shares during the period. XTX Topco Ltd acquired a new stake in Werewolf Therapeutics during the 3rd quarter worth approximately $45,000. Levin Capital Strategies L.P. acquired a new stake in Werewolf Therapeutics during the 4th quarter worth approximately $74,000. Finally, Jane Street Group LLC boosted its position in Werewolf Therapeutics by 261.2% during the 4th quarter. Jane Street Group LLC now owns 54,713 shares of the company’s stock worth $81,000 after buying an additional 39,564 shares during the period. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.